Drug Profile
Donaperminogene seltoplasmid - Helixmith
Alternative Names: Donaperminogene seltoplasmid; Engensis; Hepatocyte growth factor gene therapy-Helixmith; HGF plasmid; Modified hepatocyte growth factor gene therapy-Helixmith; NL003; pCK-HGF-X7; VM-202; VM202-ALS; VM202-CAD; VM202-DPN; VM202-PAD; VM202-Stent; VM202RYLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ViroMed Co Ltd
- Developer Beijing Northland Biotech; Helixmith; Reyon Pharmaceutical
- Class Anti-ischaemics; Foot disorder therapies; Gene therapies; Neuroprotectants; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Gene transference; Hepatocyte growth factor expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic limb-threatening ischemia; Diabetic foot ulcer; Diabetic neuropathies
- Phase II Amyotrophic lateral sclerosis; Coronary artery disease; Myocardial infarction
- Phase I/II Charcot-Marie-Tooth disease
- No development reported Ischaemic heart disorders; Myocardial ischaemia
Most Recent Events
- 05 Sep 2023 Northwestern University and ViroMed completes the phase II HI-PAD trial for Peripheral arterial disorders in USA (NCT03363165)
- 17 Jul 2023 Phase-II clinical trials in Coronary artery disease in South Korea (IM), prior to July 2023 (Reyon Pharmaceuticals pipeline, July 2023)
- 09 Jan 2023 Helixmith terminates a phase III trial in Diabetic foot ulcer in USA (IM) due to low enrollment (NCT02563522)